Vertex Pharmaceuticals (Canada) Incorporated
Registration:
1
of
1
(2023-08-22
to
2024-08-01)
Details Regarding the Identified Subject Matter
|
Specific Topics of Lobbying Communications
|
Intended Outcomes
|
Associated Subject Matters
|
• Common Drug Review, as it relates to health technology assessments and drug product reimbursement recommendations.
• Engagement on issues related to access to medicines for Rare Diseases.
|
Development or enactment of any regulation, including the enactment of a regulation for the purposes of amending or repealing a regulation, Awarding, amendment or termination of any contract, grant or financial benefit by or on behalf of the government of British Columbia or a Provincial entity
|
Economic Development and Trade, Health, Intellectual Property, Science and Technology, Taxation and Finance
|